CD274 and clear cell renal carcinoma: Motzer et al. 11 reported that PD-L1 negative group (<1%) showed a longer median PFS (27.4 months vs 21.8 months) than PD-L1 (>1%) group in advanced clear-cell renal-cell carcinoma patients treated with nivolumab.